Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.62 |
| ▸ | HRH1 | P35367 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | HRH2 | P25021 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222588 | 1.00 | CHRM2 (0.62) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL29351489 | 1.00 | CHRM2 (0.62) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL28250713 | 0.93 | CHRM2 (0.53) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL574530 | 0.91 | CHRM2 (0.67) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL4879639 | 0.91 | CHRM2 (0.67) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| Hydrochloric Acid SCHEMBL4771342 | 0.90 | CHRM2 (0.66) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL4661197 | 0.88 | CHRM2 (0.61) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL14709412 | 0.88 | CHRM2 (0.77) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL13175653 | 0.88 | CHRM2 (0.77) | CHRM2CHRM1HRH1MAPTCHRM5 | |
| SCHEMBL725535 | 0.88 | CHRM2 (0.77) | CHRM2CHRM1HRH1MAPTCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | GILEAD SCIENCES, INC. | 2010-05-06 | — | — | US | claimed |
| EP-2114972-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | Gilead Sciences, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008076269-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4387977-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240199676-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4204421-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11963967-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110124627-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011031965-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | GILEAD SCIENCES, INC. | 2010-05-06 | — | — | US | disclosed |
| EP-2114972-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | Gilead Sciences, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008076269-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CHRM2 4590/4885CHRM1 4684/4885HRH1 655/4885 |
| US-20110124627-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | CHRM2 2317/4885CHRM1 2763/4885HRH1 888/4885 |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | CHRM2 2340/4885CHRM1 3324/4885HRH1 579/4885 |
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | CHRM2 4880/4885CHRM1 4849/4885HRH1 4116/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CHRM2 4750/4885CHRM1 4825/4885HRH1 1938/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | CHRM2 4438/4885CHRM1 4017/4885HRH1 787/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CHRM2 3998/4885CHRM1 3950/4885HRH1 199/4885 |
| US-11963967-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CHRM2 4756/4885CHRM1 4826/4885HRH1 1927/4885 |
| US-20240199676-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | CHRM2 4827/4885CHRM1 4805/4885HRH1 2420/4885 |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | CHRM2 2317/4885CHRM1 2763/4885HRH1 888/4885 |
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | ADRB1, ADRB2, CHRM3 | CHRM2 5/4885CHRM1 4/4885HRH1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.